Abstract OBJECTIVE: To study the clinical characteristics and pathogens of invasive fungal infection in children. METHODS: The clinical data of 104 children who suffered from invasive fungal infections between 2008 and 2012 was retrospectively reviewed. RESULTS: Of the 104 cases, 20 occurred in neonates, 48 in infants and 36 in preschool and school-aged children (old-aged children). Prematurity (70%), hyaline membrane disease (45%) and pneumonia (30%) were commonly comorbid in the neonate group. In addition, the percentage of cases receiving total parenteral nutrition was higher in the neonate group than in the other two age groups (P<0.01). Mechanical ventilation was more frequent in neonate and infant groups than in the old-aged children (P<0.01). Hematological malignancy was the most common underlying disease, and the percentage of children who had neutropenia and accepted chemotherapy was higher in the old-aged children than in the other two age groups (P<0.05). Lung infection was the most common (61.5%), followed by sepsis (14.4%) and intestinal tract infection (12.5%), while nervous system infections were found only in old-aged children. A total of 105 strains of fungi were isolated from the 104 patients, including Candida (n=90, 85.7%), Cryptococcus (n=6) and others (n=9). The most commonly isolated species was Candida albicans (n=52, 49.5%). Non-Candida albicans Candida accounted for 36.2% (n=38). The rate of susceptibility of Candida species to 5-fluorocytosine and amphotericin B was higher than fluconazole. CONCLUSIONS: Invasive fungal infections can occur in children at various ages. There are differences in the risk factors for invasive fungal infections between age groups. Candida species are the main pathogens of childhood invasive fungal infections, and both Candida albicans and non-Candida albicans Candida are common. Fluorocytosine and amphotericin B are sensitive antifungal agents for infections caused by Candida species.
［1］Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues［J］. Clin Microbiol Infect, 2009, 15(7): 613-624.
［2］Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem［J］. Clin Microbial Rev, 2007, 20(1): 133-163.
［3］Nucci M, Marr KA. Emerging fungal diseases［J］. Clin Infect Dis, 2005, 41(4): 521-526.
［4］Manno G, Scaramuccia A, Rossi R, Coppini A, Cruciani M. Trends in antifungal use and species distribution among Candida isolates in a large paediatric hospital［J］. Int J Antimicrob Agents, 2004, 24(6): 627-628.
［7］Feja KN, Wu F, Roberts K, Loughrey M, Nesin M, Larson E, et al. Risk factors for candidemia in critically ill infants: a matched case-control study［J］. J Pediatr, 2005, 147(2): 156-161.
［8］Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients［J］. Clin Infect Dis, 2003, 37(5): 634-643.
［10］Blyth CC, Chen SC, Slavin MA, Serena C, Nguyen Q, Marriott D, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients［J］. Pediatrics, 2009, 123(5): 1360-1368.
［11］Conde-Rosa A, Amador R, Pérez-Torres D, Colón E, SánchezRivera C, Nieves-Plaza M, et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center［J］. P R Health Sci J, 2010, 29(1): 26-29.
［12］Rodríguez-Galán MC, Sotomayor CE, Cano R, Porporatto C, Renna MS, Paraje MG, et al. Immune neuroendocrine interactions during a fungal infection in immunocompetent or immunosuppressed hosts［J］. Neuroimmunomodulation, 2010, 17 (3): 188-191.
